Zhi Liu

Zhi Liu

Auto-generated profile, based on publicly available information

Zhi Liu

Department of Dermatology, University of North Carolina , Chapel Hill, NC

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2005 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PDF file
DWDavid T. Woodley
David T. Woodley
CCCarl Chang
Carl Chang
PSPayam Saadat
Payam Saadat
RRRamin Ram
Ramin Ram
ZLZhi Liu
Zhi Liu
MCMei Chen
Mei Chen

1 May 2018 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
LLLan Lin
Lan Lin
BHBin-Jin Hwang
Bin-Jin Hwang
DCDonna A. Culton
Donna A. Culton
NLNing Li
Ning Li
SBSusan Burette
Susan Burette
ZLZhi Liu
Zhi Liu

4 June 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
YZYang Zhang
Yang Zhang
BHBin-Jin Hwang
Bin-Jin Hwang
ZLZhen Liu
Zhen Liu
NLNing Li
Ning Li
KLKendall Lough
Kendall Lough
ZLZhi Liu
Zhi Liu
Significance: BP180 is a cell–cell matrix adhesion molecule and is critical for attachment of epidermis to underlying dermis. We generated a dysfunctional BP180 mouse strain (Δ NC16A mice). The Δ NC16A mice at 8 weeks start developing spontaneous itch and skin inflammation characterized by increased skin thickness, infiltrating immune cells, increased levels of IgE in circulation, proinflammatory mediators in the skin, and impaired skin barrier. Bullous pemphigoid (BP) patients also present increased TSLP in lesional skin and circulation. Our findings suggest that BP180 regulates pruritic skin inflammation. Elucidation of molecular and cellular mechanisms underlying the role of BP180 in skin inflammation should help better understanding of pathophysiology of skin inflammation and identify therapeutic targets for skin inflammatory diseases such as BP and atopic dermatitis.

1 September 2016 in Journal of Autoimmunity
Verified
Journal Article
Closed access
YZYagang Zuo
Yagang Zuo
FEFlor Evangelista
Flor Evangelista
DCDonna Culton
Donna Culton
AGAntonio Guilabert
Antonio Guilabert
LLLin Lin
Lin Lin
ZLZhi Liu
Zhi Liu

1 March 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
HFHui Fang
Hui Fang
YZYang Zhang
Yang Zhang
NLNing Li
Ning Li
GWGang Wang
Gang Wang
ZLZhi Liu
Zhi Liu
Bullous pemphigoid (BP) is an autoimmune and inflammatory skin disease associated with subepidermal blistering and autoantibodies directed against the hemidesmosomal components BP180 and BP230. Animal models of BP were developed by passively transferring anti-BP180 IgG into mice, which recapitulates the key features of human BP. Using these in vivo model systems, key cellular and molecular events leading to the BP disease phenotype are identified, including binding of pathogenic IgG to its target, complement activation of the classical pathway, mast cell degranulation, and infiltration and activation of neutrophils. Proteinases released by infiltrating neutrophils cleave BP180 and other hemidesmosome-associated proteins, causing DEJ separation. Mast cells and mast cell-derived mediators including inflammatory cytokines and proteases are increased in lesional skin and blister fluids of BP. BP animal model evidence also implicates mast cells in the pathogenesis of BP. However, recent studies questioned the pathogenic role of mast cells in autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and epidermolysis bullosa acquisita. This review highlights current knowledge on BP pathophysiology with a focus on a potential role for mast cells in BP, and mast cell-related critical issues needing to be addressed in the future.

21 August 2019 in Oncogene
Verified
Journal Article
Closed access
PDF file
BHBin-Jin Hwang
Bin-Jin Hwang
YZYang Zhang
Yang Zhang
JBJaime M. Brozowski
Jaime M. Brozowski
ZLZhen Liu
Zhen Liu
SBSusan Burette
Susan Burette
ZLZhi Liu
Zhi Liu